<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-19570" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Cisatracurium</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Strawbridge</surname>
            <given-names>Andrew D.</given-names>
          </name>
          <aff>San Antonio Uniformed Services HEC</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Khanna</surname>
            <given-names>Niloufar R.</given-names>
          </name>
          <aff>California Northstate University</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Patel</surname>
            <given-names>Preeti</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Hauser</surname>
            <given-names>Joshua M.</given-names>
          </name>
          <aff>Brooke Army Medical Center</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Andrew Strawbridge declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Niloufar Khanna declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Preeti Patel declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Joshua Hauser declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>24</day>
          <month>10</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-19570.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Cisatracurium besylate is an intermediate-acting, non-depolarizing neuromuscular blocking drug (NMBD). Cisatracurium has a benzylisoquinolinium structure and is the 1R cis-1-prime R cis isomer of atracurium. As an NMBD, it has found use as an adjunct to general anesthesia, facilitating tracheal intubation and providing skeletal muscle relaxation during surgery. Cisatracurium may also be used to provide skeletal muscle relaxation to facilitate mechanical ventilation in an intensive care unit setting but must be used with sedation. This activity reviews indications, mechanism of action, administration, contraindications, monitoring, and toxicity associated with cisatracurium and the role of the interprofessional team in caring for patients who have received cisatracurium.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the appropriate indications and contraindications for cisatracurium administration based on the patient's clinical condition and individual characteristics.</p></list-item><list-item><p>Screen patients for factors such as renal or hepatic dysfunction, electrolyte imbalances, or concurrent medications that may impact the use of cisatracurium.</p></list-item><list-item><p>Assess the efficacy and safety of cisatracurium during its administration, monitoring the patient's response to therapy and adjusting the dosage as necessary.</p></list-item><list-item><p>Communicate and collaborate with other healthcare professionals, such as anesthesiologists, pharmacists, and nurses, to ensure coordinated and safe administration of cisatracurium.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=19570&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=19570">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-19570.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Cisatracurium besylate is an intermediate-acting, non-depolarizing neuromuscular blocking drug (NMBD). Cisatracurium has a benzylisoquinoline&#x000a0;structure and is the 1R cis-1&#x02019;R cis isomer of atracurium. Metocurine and d-tubocurarine are also in the benzylisoquinoline class.<xref ref-type="bibr" rid="article-19570.r1">[1]</xref></p>
        <p>
<bold>FDA-Approved Indications</bold>
</p>
        <p>As an NMBD,&#x000a0;cisatracurium has found use as an adjunct to general anesthesia, facilitating tracheal intubation in adults and in 1-month to 12-year-old pediatric patients. Cisatracurium is indicated for providing skeletal muscle relaxation during surgery and mechanical ventilation in an intensive care unit.<xref ref-type="bibr" rid="article-19570.r2">[2]</xref><xref ref-type="bibr" rid="article-19570.r3">[3]</xref><xref ref-type="bibr" rid="article-19570.r4">[4]</xref>&#x000a0;</p>
        <p>This drug is also indicated for providing skeletal muscle relaxation during surgery via infusion in pediatric patients aged 2 and older. However, due to the time needed for the onset of action of cisatracurium, it is not advised for rapid sequence endotracheal intubation.</p>
      </sec>
      <sec id="article-19570.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Cisatracurium, like the other NMBDs, binds to the nicotinic cholinergic receptor at the muscle motor end-plate but cannot induce the conformational change necessary for ion channel opening. No end-plate potential can develop because acetylcholine cannot bind to its receptors.&#x000a0;Cisatracurium acts as a competitive antagonist to acetylcholine; acetylcholinesterase inhibitors such as neostigmine antagonize this action.</p>
        <p>The neuromuscular blocking potency of cisatracurium is roughly&#x000a0;3 times that of atracurium.<xref ref-type="bibr" rid="article-19570.r5">[5]</xref> The clinically beneficial duration of action and rate of spontaneous recovery from equipotent doses of the two drugs are similar. Continuous infusion or repeated administration of maintenance doses of cisatracurium for up to 3 hours does not correlate with the development of tachyphylaxis or cumulative neuromuscular blocking effects.</p>
        <p>Cisatracurium undergoes organ-independent Hofmann elimination&#x02014;a chemical process dependent on pH and temperature&#x02014;to form the monoquaternary acrylate metabolite and laudanosine. Patients with hypothermia, which typically occurs in surgeries needing cardiopulmonary bypass and therapeutic hypothermia, may&#x000a0;require a lower dose of cisatracurium. Alternatively, a persistently febrile patient in ARDS on a cisatracurium drip may necessitate&#x000a0;higher doses of this medication.<xref ref-type="bibr" rid="article-19570.r6">[6]</xref> Neither of these byproducts has any neuromuscular blocking activity.<xref ref-type="bibr" rid="article-19570.r7">[7]</xref><xref ref-type="bibr" rid="article-19570.r8">[8]</xref><xref ref-type="bibr" rid="article-19570.r9">[9]</xref></p>
        <p>The liver and kidney both play a minor role in eliminating cisatracurium but are primary pathways for removing metabolites. Therefore, the half-life of metabolites is longer in patients with kidney or liver dysfunction, and metabolite concentrations may be higher after long-term administration. More importantly, the values of laudanosine are significantly lower in healthy surgical patients who receive cisatracurium infusions than in patients receiving infusions of atracurium, making cisatracurium a better choice for long-term use in the ICU.</p>
        <p>The following lists diseases that can lead to hypersensitivity to NMBDs:</p>
        <list list-type="bullet">
          <list-item>
            <p>Amyotrophic lateral sclerosis</p>
          </list-item>
          <list-item>
            <p>Autoimmune disorders
<list list-type="bullet"><list-item><p>Systemic lupus erythematosus</p></list-item><list-item><p>Polymyositis</p></list-item><list-item><p>Dermatomyositis</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>Familial periodic paralysis hyperkalemia</p>
          </list-item>
          <list-item>
            <p>Guillain-Barre syndrome</p>
          </list-item>
          <list-item>
            <p>Muscular dystrophy (Duchenne type)</p>
          </list-item>
          <list-item>
            <p>Myasthenia gravis</p>
          </list-item>
          <list-item>
            <p>Myasthenic syndrome</p>
          </list-item>
          <list-item>
            <p>Myotonia
<list list-type="bullet"><list-item><p>Dystrophic</p></list-item><list-item><p>Congenital</p></list-item><list-item><p>Paramyotonia</p></list-item></list>
</p>
          </list-item>
        </list>
        <p>&#x000a0;The following lists diseases that can lead to a resistance to NMBDs:</p>
        <list list-type="bullet">
          <list-item>
            <p>Burn injury</p>
          </list-item>
          <list-item>
            <p>Cerebral palsy</p>
          </list-item>
          <list-item>
            <p>Hemiplegia (on the affected side)</p>
          </list-item>
          <list-item>
            <p>Muscular denervation (peripheral nerve injury)</p>
          </list-item>
          <list-item>
            <p>Severe chronic infection
<list list-type="bullet"><list-item><p>Tetanus</p></list-item><list-item><p>Botulism</p></list-item></list>
</p>
          </list-item>
        </list>
        <p>
<bold>Pharmacokinetics</bold>
</p>
        <p>The parent drug of cisatracurium is responsible for its neuromuscular blocking activity. After IV bolus administration, a 2-compartment open model best describes the cisatracurium plasma concentration-time profile.&#x000a0;</p>
        <p>
<bold>Distribution</bold>
</p>
        <p>Cisatracurium has a large molecular weight and high polarity.&#x000a0;The drug has a volume of distribution at a steady state (VSS) of 145 mL/kg. As cisatracurium rapidly degraded at physiologic pH, plasma protein binding of cisatracurium has not been studied successfully.&#x000a0;</p>
        <p>
<bold>Elimination</bold>
</p>
        <p>Elimination based on a chemical process due to temperature and pH (Organ-independent Hofmann elimination) is the key pathway for cisatracurium elimination. The kidney and liver play a minor role in cisatracurium elimination; however, they are primary pathways for metabolite elimination. Therefore, metabolite half-life is longer in patients with renal or hepatic impairment. In studies of healthy surgical patients, average clearance values ranged from 4.5 to 5.7 mL/min/kg for cisatracurium. In studies of healthy surgical patients, the average half-life of cisatracurium ranged from 22 to 29 minutes.</p>
        <p>
<bold>Metabolism</bold>
</p>
        <p>The degradation of cisatracurium was mainly independent of liver metabolism. Suggestions have been made that cisatracurium undergoes Hofmann elimination to form laudanosine based on in vitro experiments. Laudanosine metabolite has been noted to cause transient hypotension and cerebral excitatory effects in higher doses when administered to several animal species. However, the relationship between laudanosine concentrations and CNS excitation has not been established in humans.</p>
        <p>
<bold>Excretion</bold>
</p>
        <p>According to a study involving&#x000a0;6 healthy male patients, most of the administered dose of 14C-cisatracurium (approximately 95%) was found in their urine, while 4% was in their feces. Furthermore, less than 10% of the excreted dose in the urine remained in its&#x000a0;parent form.</p>
      </sec>
      <sec id="article-19570.s4" sec-type="Administration">
        <title>Administration</title>
        <p>Cisatracurium is administered intravenously.&#x000a0;The typical dose for intubation is 0.15 to 0.2 mg/kg. After this usual dose, ideal intubating conditions are generally achievable between 1.5 and 2 minutes. The clinically effective duration of an intubating dose lasts 55 to 65 minutes. Maintenance dosing by bolus is 0.02 mg/kg. Maintaining paralysis via infusion with cisatracurium is at 1 to 3 mcg/kg/min, although adjusting the dosing based on peripheral nerve monitoring is important.<xref ref-type="bibr" rid="article-19570.r10">[10]</xref></p>
        <p>
<bold>Specific Patients Population</bold>
</p>
        <p><bold>Hepatic impairment:&#x000a0;</bold>Hepatic impairment analysis of cisatracurium was summarized from a study of 11 healthy adult patients undergoing elective surgery and 13 patients undergoing liver transplantation with end-stage liver disease. A slightly larger distribution volume is observed in liver transplant patients due to a slightly faster rate of cisatracurium plasma clearances. There was no difference in half-life, keo, or EC50 values between patient groups. Approximately one minute faster neuromuscular blockade response was observed in liver transplant patients than in healthy adult patients who received 0.1 mg/kg of cisatracurium. However, half-life values of metabolites are longer in patients with hepatic disease, and higher concentrations may be observed after long-term administration of cisatracurium.</p>
        <p><bold>Renal impairment:&#x000a0;</bold>Renal impairment analysis of cisatracurium was summarized from a study of 13 healthy adult patients undergoing elective surgery and 15 patients with end-stage renal disease. No significant difference was observed in PK/PD parameters of cisatracurium between healthy adults and end-stage renal disease patients. Approximately one minute slower response to block 90% neuromuscular was observed in end-stage renal disease patients than in healthy adult patients who received 0.1 mg/kg of cisatracurium. There were no differences in recovery rates or cisatracurium durations between healthy adults and end-stage renal disease patients.</p>
        <p>However, half-life values of metabolites are longer in patients with end-stage renal disease, and higher concentrations may be observed after long-term administration of cisatracurium. Based on Population PK analyses, patients with creatinine clearances less than 70 mL/min had a slower equilibration rate between plasma concentrations and the effect of the neuromuscular block than normal renal function patients. There was no clinically significant change in the cisatracurium recovery profile in patients with renal impairment.&#x000a0;</p>
        <p><bold><bold>Pregnancy:&#x000a0;</bold></bold>No well-controlled and adequate studies of cisatracurium have been conducted in pregnant women. The risk of major congenital abnormalities&#x000a0;and miscarriage is unknown in the indicated population. Using magnesium salts to manage preeclampsia or eclampsia during pregnancy may enhance the effect of neuromuscular blocking agents.&#x000a0;Recommendations for administering cisatracurium for prolonged neuromuscular blockade in critically ill pregnant patients are unavailable due to lack of evidence.<xref ref-type="bibr" rid="article-19570.r4">[4]</xref></p>
        <p><bold>Breastfeeding:&#x000a0;</bold>The presence of cisatracurium in human milk is unknown. The health and developmental benefits of breastfeeding must be considered before initiating the clinical use of cisatracurium in breastfeeding women.&#x000a0;The recommendation&#x000a0;is&#x000a0;to monitor&#x000a0;any potential negative impacts on the breastfed infant that may arise from cisatracurium or the mother's underlying medical condition.<xref ref-type="bibr" rid="article-19570.r1">[1]</xref><xref ref-type="bibr" rid="article-19570.r11">[11]</xref>&#x000a0;Generally, neuromuscular&#x000a0;blocking medicines may be used in lactating females depending on their physical characteristics and poor oral bioavailability.<xref ref-type="bibr" rid="article-19570.r12">[12]</xref></p>
        <p><bold>Pediatric patients:&#x000a0;</bold>The effect of cisatracurium in pediatric patients was summarized from a population PK/PD study of 12 healthy pediatric patients of 2 to 12 years old and 12 healthy adult patients. Higher clearance was observed in healthy pediatric patients (5.89 mL/min/kg) compared to healthy adult patients (4.57 mL/min/kg). The minor difference in the PK/PD parameters of cisatracurium may be due to a shorter duration of neuromuscular blockade action and a faster time to onset in pediatric patients.</p>
        <p><bold>Older patients:&#x000a0;</bold>The effect of cisatracurium in&#x000a0;older patients was summarized from a study of 12 healthy&#x000a0;older patients and 12 healthy adult patients who received a single IV cisatracurium dose of 0.1 mg/kg. Cisatracurium plasma clearances were unaffected by age; however, a slightly larger volume of distribution was observed in&#x000a0;older patients than in young patients, which may lead to slightly longer half-life values for cisatracurium. The equilibration rate between the plasma cisatracurium concentrations and neuromuscular blockade was slower in&#x000a0;older than young patients. There are only minor differences in pharmacokinetics and pharmacodynamic parameters of cisatracurium between&#x000a0;older&#x000a0;and young patients.</p>
      </sec>
      <sec id="article-19570.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>Adverse effects are uncommon with the use of cisatracurium. Adverse reactions occurred at a rate&#x000a0;of less than 1% and included bradycardia, hypotension, bronchospasm, rash, anaphylaxis, prolonged neuromuscular blockade, and myopathy.<xref ref-type="bibr" rid="article-19570.r13">[13]</xref></p>
        <p>No clinically relevant alterations in the recovery profile were observed in patients with renal dysfunction or end-stage liver disease, making cisatracurium a good choice for patients with either of these diseases.</p>
      </sec>
      <sec id="article-19570.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Cisatracurium is contraindicated if there is a known hypersensitivity. Caution is advised in patients with myasthenia gravis or myasthenic syndrome, as a profound effect may occur.</p>
        <p>Severe anaphylactic reactions to NMBDs, including cisatracurium, have been reported. Precautions are also advisable in those patients with a history of prior anaphylactic reactions to neuromuscular blocking agents, as there are reports of cross-reactivity in the neuromuscular blocking agent drug class with depolarizing and nondepolarizing agents.</p>
        <p>Cisatracurium should be kept refrigerated at 2 to 8 &#x000b0;C and protected from light to preserve potency. The potency loss rate is as high as 5% monthly at 25&#x000b0;C. Once removed from refrigeration to room temperature storage, it should be used within 21 days.</p>
      </sec>
      <sec id="article-19570.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>The standard of care for monitoring while using all NMBDs is to use peripheral nerve stimulation. The most common locations to place the electrodes are over the facial nerve on the lateral face, the ulnar nerve at the medial wrist, or the posterior tibial nerve at the medial ankle. Stimulation of these nerves causes muscular contraction of the orbicularis oculi, adductor pollicis, and flexor hallucis&#x000a0;longus, respectively. Peripheral nerve stimulation measuring a twitch response should measure the depth of muscle paralysis.</p>
        <p>The most common pattern to test nerve stimulation is with a train of four (TOF), but sustained tetanus, and double burst stimulation (DBS) is another option. TOF stimulation is four repetitive electrical impulses of 2 Hz in 2 seconds. In the presence of NMBDs, repetitive stimulation causes a diminished release of acetylcholine at the neuromuscular junction, leading to a decreased amplitude of muscle contraction. With the return of the TOF ratio to 0.9, esophageal tone and pharyngeal coordination returned toward baseline.<xref ref-type="bibr" rid="article-19570.r14">[14]</xref><xref ref-type="bibr" rid="article-19570.r15">[15]</xref><xref ref-type="bibr" rid="article-19570.r16">[16]</xref></p>
      </sec>
      <sec id="article-19570.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>Overdose with cisatracurium may result in neuromuscular blockade beyond the time needed for surgery and anesthesia.&#x000a0;The primary treatment is maintaining sedation, a patent airway, and controlled ventilation until recovery of neuromuscular function is assured. There should be no attempt at reversal if there is evidence or suspicion of complete neuromuscular blockade.</p>
        <p>Once recovery from blockade begins, from the evidence of peripheral nerve stimulation, the neuromuscular blockade may be reversed with an anticholinesterase agent (eg, neostigmine) in conjunction with an anticholinergic agent (eg, glycopyrrolate). As with other nondepolarizing neuromuscular blocking agents, the more full the neuromuscular blockade at the point of reversal, the longer the time required for recovery of neuromuscular function. A typical dose of neostigmine is 0.03 to 0.07 mg/kg, in conjunction with 0.2 mg glycopyrrolate for every 1 mg of neostigmine.<xref ref-type="bibr" rid="article-19570.r17">[17]</xref></p>
      </sec>
      <sec id="article-19570.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Cisatracurium should be administered only by adequately trained individuals (ie, anesthesiologist,&#x000a0;nurse anesthetist, intensivist, emergency physician) familiar with its actions, characteristics, and hazards. The drug should not be administered&#x000a0;without the presence of personnel and facilities for resuscitation, and life support and an antagonist for cisatracurium must be immediately available.</p>
        <p>Cisatracurium dosing should be individualized, and a peripheral nerve stimulator should be used to measure neuromuscular function during the administration of cisatracurium to monitor the drug's effect. This monitoring will&#x000a0;determine the need for additional doses and confirm recovery from neuromuscular block. Cisatracurium has no known effects on consciousness or pain threshold, so to avoid patient distress, a neuromuscular block should not be induced before unconsciousness. This medication is most effective and safest when used&#x000a0;with an interprofessional team administering the drug and monitoring the patient.</p>
      </sec>
      <sec id="article-19570.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=19570&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=19570">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/19570/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=19570">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-19570.s11">
        <title>References</title>
        <ref id="article-19570.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hunter</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <article-title>New neuromuscular blocking drugs.</article-title>
            <source>N Engl J Med</source>
            <year>1995</year>
            <month>Jun</month>
            <day>22</day>
            <volume>332</volume>
            <issue>25</issue>
            <fpage>1691</fpage>
            <page-range>1691-9</page-range>
            <pub-id pub-id-type="pmid">7760871</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19570.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Forel</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Roch</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Marin</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Michelet</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Demory</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Blache</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Perrin</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Gainnier</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bongrand</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Papazian</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Neuromuscular blocking agents decrease inflammatory response in patients presenting with acute respiratory distress syndrome.</article-title>
            <source>Crit Care Med</source>
            <year>2006</year>
            <month>Nov</month>
            <volume>34</volume>
            <issue>11</issue>
            <fpage>2749</fpage>
            <page-range>2749-57</page-range>
            <pub-id pub-id-type="pmid">16932229</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19570.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Alhazzani</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Belley-Cote</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>M&#x000f8;ller</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Angus</surname>
                <given-names>DC</given-names>
              </name>
              <name>
                <surname>Papazian</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Arabi</surname>
                <given-names>YM</given-names>
              </name>
              <name>
                <surname>Citerio</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Connolly</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Denehy</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Fox-Robichaud</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hough</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Laake</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Machado</surname>
                <given-names>FR</given-names>
              </name>
              <name>
                <surname>Ostermann</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Piraino</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Sharif</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Szczeklik</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Young</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Gouskos</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kiedrowski</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Burns</surname>
                <given-names>KEA</given-names>
              </name>
            </person-group>
            <article-title>Neuromuscular blockade in patients with ARDS: a rapid practice guideline.</article-title>
            <source>Intensive Care Med</source>
            <year>2020</year>
            <month>Nov</month>
            <volume>46</volume>
            <issue>11</issue>
            <fpage>1977</fpage>
            <page-range>1977-1986</page-range>
            <pub-id pub-id-type="pmid">33104824</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19570.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Murray</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>DeBlock</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Erstad</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Gray</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Jacobi</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Jordan</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>McGee</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>McManus</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Meade</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Nix</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Patterson</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sands</surname>
                <given-names>MK</given-names>
              </name>
              <name>
                <surname>Pino</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Tescher</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Arbour</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Rochwerg</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Murray</surname>
                <given-names>CF</given-names>
              </name>
              <name>
                <surname>Mehta</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Clinical Practice Guidelines for Sustained Neuromuscular Blockade in the Adult Critically Ill Patient.</article-title>
            <source>Crit Care Med</source>
            <year>2016</year>
            <month>Nov</month>
            <volume>44</volume>
            <issue>11</issue>
            <fpage>2079</fpage>
            <page-range>2079-2103</page-range>
            <pub-id pub-id-type="pmid">27755068</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19570.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wastila</surname>
                <given-names>WB</given-names>
              </name>
              <name>
                <surname>Maehr</surname>
                <given-names>RB</given-names>
              </name>
              <name>
                <surname>Turner</surname>
                <given-names>GL</given-names>
              </name>
              <name>
                <surname>Hill</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Savarese</surname>
                <given-names>JJ</given-names>
              </name>
            </person-group>
            <article-title>Comparative pharmacology of cisatracurium (51W89), atracurium, and five isomers in cats.</article-title>
            <source>Anesthesiology</source>
            <year>1996</year>
            <month>Jul</month>
            <volume>85</volume>
            <issue>1</issue>
            <fpage>169</fpage>
            <page-range>169-77</page-range>
            <pub-id pub-id-type="pmid">8694363</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19570.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cammu</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Coddens</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hendrickx</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Deloof</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Dose requirements of infusions of cisatracurium or rocuronium during hypothermic cardiopulmonary bypass.</article-title>
            <source>Br J Anaesth</source>
            <year>2000</year>
            <month>May</month>
            <volume>84</volume>
            <issue>5</issue>
            <fpage>587</fpage>
            <page-range>587-90</page-range>
            <pub-id pub-id-type="pmid">10844834</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19570.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Prielipp</surname>
                <given-names>RC</given-names>
              </name>
              <name>
                <surname>Coursin</surname>
                <given-names>DB</given-names>
              </name>
              <name>
                <surname>Scuderi</surname>
                <given-names>PE</given-names>
              </name>
              <name>
                <surname>Bowton</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Ford</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Cardenas</surname>
                <given-names>VJ</given-names>
              </name>
              <name>
                <surname>Vender</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Howard</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Casale</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Murray</surname>
                <given-names>MJ</given-names>
              </name>
            </person-group>
            <article-title>Comparison of the infusion requirements and recovery profiles of vecuronium and cisatracurium 51W89 in intensive care unit patients.</article-title>
            <source>Anesth Analg</source>
            <year>1995</year>
            <month>Jul</month>
            <volume>81</volume>
            <issue>1</issue>
            <fpage>3</fpage>
            <page-range>3-12</page-range>
            <pub-id pub-id-type="pmid">7598277</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19570.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>P&#x000fc;hringer</surname>
                <given-names>FK</given-names>
              </name>
              <name>
                <surname>Heier</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Dodgson</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Erkola</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Goonetilleke</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Hofmockel</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Gaetke</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Mortensen</surname>
                <given-names>CR</given-names>
              </name>
              <name>
                <surname>Upadhyaya</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Eriksson</surname>
                <given-names>LI</given-names>
              </name>
            </person-group>
            <article-title>Double-blind comparison of the variability in spontaneous recovery of cisatracurium- and vecuronium-induced neuromuscular block in adult and elderly patients.</article-title>
            <source>Acta Anaesthesiol Scand</source>
            <year>2002</year>
            <month>Apr</month>
            <volume>46</volume>
            <issue>4</issue>
            <fpage>364</fpage>
            <page-range>364-71</page-range>
            <pub-id pub-id-type="pmid">11952434</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19570.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Arain</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Kern</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ficke</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Ebert</surname>
                <given-names>TJ</given-names>
              </name>
            </person-group>
            <article-title>Variability of duration of action of neuromuscular-blocking drugs in elderly patients.</article-title>
            <source>Acta Anaesthesiol Scand</source>
            <year>2005</year>
            <month>Mar</month>
            <volume>49</volume>
            <issue>3</issue>
            <fpage>312</fpage>
            <page-range>312-5</page-range>
            <pub-id pub-id-type="pmid">15752394</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19570.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bluestein</surname>
                <given-names>LS</given-names>
              </name>
              <name>
                <surname>Stinson</surname>
                <given-names>LW</given-names>
              </name>
              <name>
                <surname>Lennon</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Quessy</surname>
                <given-names>SN</given-names>
              </name>
              <name>
                <surname>Wilson</surname>
                <given-names>RM</given-names>
              </name>
            </person-group>
            <article-title>Evaluation of cisatracurium, a new neuromuscular blocking agent, for tracheal intubation.</article-title>
            <source>Can J Anaesth</source>
            <year>1996</year>
            <month>Sep</month>
            <volume>43</volume>
            <issue>9</issue>
            <fpage>925</fpage>
            <page-range>925-31</page-range>
            <pub-id pub-id-type="pmid">8874910</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19570.r11">
          <label>11</label>
          <element-citation publication-type="book">
            <chapter-title>Cisatracurium</chapter-title>
            <source>Drugs and Lactation Database (LactMed&#x000ae;) [Internet]</source>
            <publisher-name>National Institute of Child Health and Human Development</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2022</year>
            <month>11</month>
            <day>30</day>
            <pub-id pub-id-type="pmid">29999740</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19570.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Reece-Stremtan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Campos</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kokajko</surname>
                <given-names>L</given-names>
              </name>
              <collab>Academy of Breastfeeding Medicine</collab>
            </person-group>
            <article-title>ABM Clinical Protocol #15: Analgesia and Anesthesia for the Breastfeeding Mother, Revised 2017.</article-title>
            <source>Breastfeed Med</source>
            <year>2017</year>
            <month>Nov</month>
            <volume>12</volume>
            <issue>9</issue>
            <fpage>500</fpage>
            <page-range>500-506</page-range>
            <pub-id pub-id-type="pmid">29624435</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19570.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Konstadt</surname>
                <given-names>SN</given-names>
              </name>
              <name>
                <surname>Reich</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Stanley</surname>
                <given-names>TE</given-names>
              </name>
              <name>
                <surname>DePerio</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Chuey</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Schwartzbach</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Abou-Donia</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>A two-center comparison of the cardiovascular effects of cisatracurium (Nimbex) and vecuronium in patients with coronary artery disease.</article-title>
            <source>Anesth Analg</source>
            <year>1995</year>
            <month>Nov</month>
            <volume>81</volume>
            <issue>5</issue>
            <fpage>1010</fpage>
            <page-range>1010-4</page-range>
            <pub-id pub-id-type="pmid">7486039</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19570.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Butterly</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bittner</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>George</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Sandberg</surname>
                <given-names>WS</given-names>
              </name>
              <name>
                <surname>Eikermann</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Schmidt</surname>
                <given-names>U</given-names>
              </name>
            </person-group>
            <article-title>Postoperative residual curarization from intermediate-acting neuromuscular blocking agents delays recovery room discharge.</article-title>
            <source>Br J Anaesth</source>
            <year>2010</year>
            <month>Sep</month>
            <volume>105</volume>
            <issue>3</issue>
            <fpage>304</fpage>
            <page-range>304-9</page-range>
            <pub-id pub-id-type="pmid">20576632</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19570.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Murphy</surname>
                <given-names>GS</given-names>
              </name>
            </person-group>
            <article-title>Neuromuscular Monitoring in the Perioperative Period.</article-title>
            <source>Anesth Analg</source>
            <year>2018</year>
            <month>Feb</month>
            <volume>126</volume>
            <issue>2</issue>
            <fpage>464</fpage>
            <page-range>464-468</page-range>
            <pub-id pub-id-type="pmid">28795964</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19570.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Murphy</surname>
                <given-names>GS</given-names>
              </name>
              <name>
                <surname>Szokol</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Avram</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Greenberg</surname>
                <given-names>SB</given-names>
              </name>
              <name>
                <surname>Marymont</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Vender</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Gray</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Landry</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Gupta</surname>
                <given-names>DK</given-names>
              </name>
            </person-group>
            <article-title>Intraoperative acceleromyography monitoring reduces symptoms of muscle weakness and improves quality of recovery in the early postoperative period.</article-title>
            <source>Anesthesiology</source>
            <year>2011</year>
            <month>Nov</month>
            <volume>115</volume>
            <issue>5</issue>
            <fpage>946</fpage>
            <page-range>946-54</page-range>
            <pub-id pub-id-type="pmid">21946094</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19570.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Li</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Yao</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Xie</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>A comparison of neuromuscular blockade and reversal using cisatricurium and neostigmine with rocuronium and sugamadex on the quality of recovery from general anaesthesia for percutaneous closure of left atria appendage.</article-title>
            <source>J Cardiothorac Surg</source>
            <year>2022</year>
            <month>Aug</month>
            <day>26</day>
            <volume>17</volume>
            <issue>1</issue>
            <fpage>211</fpage>
            <pub-id pub-id-type="pmid">36028870</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
